Back to Journals » OncoTargets and Therapy » Volume 10

Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma

Total article views   Abstract views HTML views PDF downloads Totals
4,934 Dovepress* 3,475 591+ 1,288 4,066
PubMed Central* 0 868 540 868
Totals 3,475 1,459 1,828 4,934
*Since 18 January 2017
+Since July 2016

View citations on PubMed Central and Google Scholar